Induction of Meiosis from Human Pluripotent Stem Cells

Merrick D Pierson Smela,Jessica Adams,Carl Ma,Laura Breimann,Ursula Widocki,Toshihiro Shioda,George Church

DOI: https://doi.org/10.1101/2024.05.31.596483

2024-06-01

Abstract:An in vitro model of human meiosis would accelerate research into this important reproductive process and development of therapies for infertility. We have developed a method to induce meiosis starting from male or female human pluripotent stem cells. We demonstrate that DNMT1 inhibition, retinoid signaling activation, and overexpression of regulatory factors (anti-apoptotic BCL2, and pro-meiotic HOXB5, BOLL, or MEIOC) rapidly activates meiosis, with leptonema beginning at 6 days, zygonema at 9 days, and pachynema at 12 days. Immunofluorescence microscopy shows key aspects of meiosis, including chromosome synapsis and sex body formation. The meiotic cells express genes similar to meiotic oogonia in vivo, including all synaptonemal complex components and machinery for meiotic recombination. These findings establish an accessible system for inducing human meiosis in vitro.

Synthetic Biology

What problem does this paper attempt to address?

This paper aims to address the issue of inducing human meiosis in vitro. Specifically, the research team developed a method to induce meiosis from male or female human pluripotent stem cells (hPSCs). By inhibiting DNA methyltransferase 1 (DNMT1), activating the retinoic acid signaling pathway, and overexpressing regulatory factors (such as the anti-apoptotic factor BCL2 and pro-meiotic factors HOXB5, BOLL, or MEIOC), leptonema can be observed starting at 6 days, zygonema at 9 days, and pachynema at 12 days. This method provides a new experimental system for studying the human meiotic process and may contribute to the development of new therapies for infertility.